pancreatitis symptoms semaglutide What are the risks of associated with Wegovy (semaglutide)? Pancreatitis Symptoms

This study suggests a slightly increased risk of a rare but serious eye condition among people with type 2 diabetes starting GLP-1 receptor agonists compared with those starting SGLT-2 inhibitors or DPP-4 inhibitors

L- 500-2000

Their research highlights that the body has two GLP-1 systems

The key mechanisms include: Appetite suppression: Semaglutide acts on hypothalamic centers in the brain to reduce hunger and increase satiety Delayed gastric emptying: Food moves through the stomach more slowly, prolonging the feeling of fullness Improved insulin sensitivity: Better glucose regulation reduces insulin-driven fat storage Reduced food reward signaling: Semaglutide appears to decrease the neurological reward response to food In the STEP 1 clinical trial, participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% with placebo (Wilding et al., 2021, New England Journal of Medicine )

This means that over time, your pain management needs may actually decrease as your treatment progresses